Wird geladen...
Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers
In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Landes Bioscience
2013
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/ https://ncbi.nlm.nih.gov/pubmed/23760495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|